Who is sponsoring NCT02791412?

NCT02791412 is sponsored by Seung-Jung Park.

What drugs are being tested in NCT02791412?

Interventions in NCT02791412: percutaneous coronary intervention or coronary-artery bypass graft.

What condition does NCT02791412 study?

NCT02791412 studies Coronary Arteries.

Is NCT02791412 still recruiting?

NCT02791412 is currently completed. Last updated 26 June 2018.

Last reviewed 2018-06-26 · How we verify

NCT02791412: MAIN COMPARE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ten-Year Outcomes of Stents Versus Coronary-Artery Bypass Grafting for Left Main Coronary Artery Disease

Completed Last updated 26 June 2018

What this trial tests

trial testing percutaneous coronary intervention or coronary-artery bypass graft in Coronary Arteries in 2,240 participants. Completed in 30 May 2018.

Timeline

13 January 2017

Primary endpoint
30 May 2018

30 May 2018

Quick facts

Lead sponsor	Seung-Jung Park
Status	Completed
Study type	OBSERVATIONAL
Enrollment	2,240
Start date	13 January 2017
Primary completion	30 May 2018
Estimated completion	30 May 2018
Sites	12 locations across South Korea

Drugs / interventions tested

percutaneous coronary intervention or coronary-artery bypass graft

Conditions studied

Coronary Arteries — all drugs for Coronary Arteries →

Sponsor

Seung-Jung Park — full company profile →

Who can join

19 and older, any sex, with Coronary Arteries. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate long-term outcome of treatment(percutaneous coronary intervention or coronary-artery bypass graft) in unprotected left main coronary artery stenosis in Korea.

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

10-Year Outcomes of Stents Versus Coronary Artery Bypass Grafting for Left Main Coronary Artery Disease.
Park DW, Ahn JM, Yun SC, Yoon YH, et al · · 2018 · cited 65× · PMID 30261236 · DOI 10.1016/j.jacc.2018.09.012
Impact of SYNTAX Score on 10-Year Outcomes After Revascularization for Left Main Coronary Artery Disease.
Yoon YH, Ahn JM, Kang DY, Park H, et al · · 2020 · cited 22× · PMID 32029254 · DOI 10.1016/j.jcin.2019.10.020
Long-Term (10-Year) Outcomes of Stenting or Bypass Surgery for Left Main Coronary Artery Disease in Patients With and Without Diabetes Mellitus.
Lee K, Ahn JM, Yoon YH, Kang DY, et al · · 2020 · cited 19× · PMID 32310027 · DOI 10.1161/jaha.119.015372
Impact of Target Lesion Revascularization on Long-Term Mortality After Percutaneous Coronary Intervention for Left Main Disease.
Kim TO, Kang DY, Ahn JM, Kim MJ, et al · · 2024 · cited 4× · PMID 38199751 · DOI 10.1016/j.jcin.2023.10.068
Time-Dependent Impact of Sex on the Long-Term Outcomes After Left Main Revascularization.
Yoon YH, Ahn JM, Lee JB, Kang DY, et al · · 2022 · cited 4× · PMID 35189706 · DOI 10.1161/jaha.121.021720
Very Long-term Safety and Effectiveness of Drug-Eluting or Bare-Metal Stents for Left Main Coronary Disease.
Park H, Ahn JM, Kang DY, Kim SO, et al · · 2021 · cited 3× · PMID 34888503 · DOI 10.1016/j.cjco.2021.05.009

Verify or expand the search:

Other Seung-Jung Park trials

Trials by the same sponsor.

NCT06908499 — The DECISION-CTO Extended 10 Y Follow-up · not yet recruiting
NCT06177743 — IRIS-Coroflex NEO Cohort · recruiting
NCT05125367 — Ten-Year Outcomes of Randomized Comparison of Coronary Artery Bypass Surgery and Everolimus-Eluting Stent Implantation i · completed
NCT03967158 — Evaluation of Effectiveness and Safety of XIENCE Sierra in Routine Clinical Practice · active not recruiting
NCT03190057 — IRIS-BioFreedom Cohort in the IRIS-DES Registry · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02791412 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Seung-Jung Park
Last refreshed: 26 June 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02791412.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing